Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity - Concepedia

Concepedia

Publication | Closed Access

Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity

189

Citations

31

References

2019

Year

Thomas Dörner, Maximilian Posch, Yue Li, Olivier Pétricoul, Maciej Cabanski, Julie Milojevic, Esther Kamphausen, Marie‐Anne Valentin, Claudia Simonett, Louise Mooney,

Annals of the Rheumatic Diseases

References

	Year	Citations

Page 1